ProCE Banner Activity

Selecting Therapy for AML With Predictive Biomarkers or Actionable Alterations

Slideset Download

Download these slides from a live symposium for the most recent data on selecting AML therapy for patients with predictive biomarkers or actionable alterations.

Released: December 09, 2022

Expiration: December 08, 2023

Share

Faculty

Eytan M. Stein

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Astellas Text

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Servier Pharmaceuticals

Syndax

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Eytan M. Stein, MD: consultant/advisor/speaker: AbbVie, Agios, Aptose, Astellas, Blueprint, Bristol Myers Squibb, Calithera, CTI Biopharma, Daiichi Sankyo, Foghorn, Genentech, Genesis, Gilead, Janssen, Jazz Pharmaceuticals, Kura, Menarini, Neoleukin, Novartis, OnCusp, Ono Pharma, PinotBio, Servier, Syndax, Syros; data and safety monitoring board: Cellectis, Epizyme; researcher: Bristol Myers Squibb, Eisai; stock/stock options: Auron.